Iconic Therapeutics

News

NICE’s track record in cancer drugs: the impact of the CDF and the role of interim funding

Exelixis takes $20m option Iconic/Zymeworks' cancer ADC

Exelixis has taken a $20 million option to license in an antibody-drug conjugate cancer (ADC) drug from Iconic, with clinical trials expected to start next year.

News

Neurosterix' $105m round leads the week's biotech financings

Neurosterix raises $105m for its schizophrenia candidate, as Delix, VectorY, and Eli Radiopharma also add to their cash reserves.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/register.png

Sales & Marketing

Securing your ROI: Turning post-acquisition integration into...

Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.

Editor's Picks